Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2007

View Archived Issues

New therapeutic agents for cancer covered in recent patent literature

Trodusquemine reduces weight, adiposity and improves plasma insulin and leptin in DIO mice

Recent patents disclose novel antiinfective agents

Recent clinical results with new insulin formulations

Mitochondrial voltage-dependent anion channels appear as new targets in cancer therapy

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Algeta initiates clinical dosimetry study with Alpharadin in HRPC patients

Surface Logix evaluates long-acting PDE-5 inhibitors for cardiovascular indications

The Medicines Company reacquires Angiox in Europe

MerLion begins phase I clinical study of antibiotic friulimicin B

Update on Advanced Life Sciences' phase III trial of cethromycin

Positive phase II results for Anesiva's drug candidate Adlea

Maxygen begins phase IIa trial of MAXY-G34 for breast cancer

Pan-PPAR agonist may be beneficial in accelerated atherosclerosis

Studies show favorable pharmacokinetics, reduced costs with CERA

Snapshots of acute and prophylactic treatments for migraine

Clinical trials with natural products in psoriasis

Clinical trials on rhGH formulations reported at ESPE

CYT003-QbG10 shows no treatment effect in atopic dermatitis

Wyeth assumes European marketing and distribution rights for BeneFIX

NICE recommends Tysabri in highly active relapsing remitting MS

Daivobet Scalp gel filed for scalp psoriasis in U.S. and E.U.

EpiCept accelerates clinical trials of EPC-2407 in cancer

Medtronic's ENDEAVOR IV clinical trial meets primary endpoint

Regulatory guidance on pivotal program for Chronocort

Azur licenses FazaClo rights from Avanir

Japanese priority review for Plavix sNDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...